Theralase Technologies Inc.
TLTFF
$0.11
$0.003.64%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 718.50K | 769.60K | 684.50K | 751.20K | 725.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 718.50K | 769.60K | 684.50K | 751.20K | 725.30K |
| Cost of Revenue | 320.30K | 339.50K | 319.70K | 349.50K | 350.40K |
| Gross Profit | 398.40K | 430.30K | 364.90K | 401.70K | 374.90K |
| SG&A Expenses | 1.57M | 1.55M | 1.53M | 1.53M | 1.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.86M | 3.87M | 3.91M | 3.89M | 3.93M |
| Operating Income | -3.14M | -3.10M | -3.23M | -3.13M | -3.21M |
| Income Before Tax | -3.10M | -3.06M | -3.20M | -3.11M | -3.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.10 | -3.06 | -3.20 | -3.11 | -3.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.10M | -3.06M | -3.20M | -3.11M | -3.18M |
| EBIT | -3.14M | -3.10M | -3.23M | -3.13M | -3.21M |
| EBITDA | -3.02M | -2.98M | -3.10M | -3.01M | -3.08M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.00B | 987.38M | 970.73M | 952.39M | 922.37M |
| Average Diluted Shares Outstanding | 1.00B | 987.38M | 970.73M | 952.39M | 922.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |